GET THE APP

A Rare Presentation Of Checkpoint Inhibitor Induced RTA | SciTechnol

Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report, Clin Oncol Case Rep Vol: 4 Issue: 6

A Rare Presentation Of Checkpoint Inhibitor Induced RTA

Andrew V Doodnauth1, Miriam M. Klar1, Zohra Malik2, Krunal H. Patel1, Daniela Tello1, Safi Afzal3 and Samy I McFarlane1*

1Department of Internal Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, New York, United States

2Department of Internal Medicine, St. John's Episcopal Hospital, Far Rockaway, New York, United States

3Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States

*Corresponding Author : Samy I McFarlane
Samy I McFarlane, Department of Medicine, Division of Endocrinology, Internal Medicine Residency Program Director, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Box 50, Brooklyn, NY 11203-2098
E-mail: smcfarlane@downstate.edu

Received: May 07, 2021 Accepted: June 23, 2021 Published: June 30, 2021

Citation: Doodnauth AV, Klar MM, Malik Z, Patel KH, Tello D, et al. (2021) A Rare Presentation of Checkpoint Inhibitor Induced RTA. Clin Oncol Case Rep 4:6.

Abstract

Immune checkpoint inhibitors have opened a new era in the treatment of advanced malignancies, resulting in increased use and remarkable clinical responses. However, there has been an increase in the incidence of immune-related adverse events as a result of the immunologic effects of these therapies. Kidney immune-related adverse events incidence is reported as low at 2% to 5%1. Renal toxicity commonly described includes acute interstitial nephritis, minimal change disease, immune complex glomerulonephritis2. Renal tubular acidosis (RTA) has occasionally been reported but is uncommon. We report a patient with a known history of metastatic melanoma undergoing treatment with Ipilimumab + Nivolumab who developed an RTA and was successfully treated with stress dose steroids and sodium bicarbonate. To date, there are a limited number of reports describing immune-related adverse events causing RTA. We describe the clinical characteristics, potential mechanisms, and management of patients who develop an immune-related RTA.

Keywords: Immune checkpoint inhibitors; Immune-related adverse event; Renal tubular acidosis; Ipilimumab; Nivolumab

Track Your Manuscript

Google scholar citation report